As the array of novel therapies for plaque psoriasis expands, a strategy to navigate treatment options is to focus on the specific needs of different patient groups, like Medicare-aged patients. ILUMYA® (tildrakizumab-asmn) is the only biologic for plaque psoriasis guaranteed to be covered under the medical benefit of Medicare, with no prior authorization and zero cost as a likely possibility. Join Dr Charles Turck and Dr John Koo as they share insights on the efficacy, safety, and accessibility of ILUMYA in this patient population. Dr. Koo is a Professor of Dermatology at the University of California at San Francisco School of Medicine.